The PSOC Administrative Core will manage and coordinate all Center research and activities and serve as the liaisons between the Centers and the Network. The DFCI-PSOC has organized a leadership structure to provide expertise and fully support all initiatives within the DFCI-PSOC and PSOC network. The leadership consists of two PIs, Franziska Michor, PhD, and Eric Holland, MD, PhD. Support personnel consists of the Center Administrator/Education Director, Jessica Daniels, MA, who possesses strong project management capabilities. The PSOC leadership and support personnel, also known as the Administration, will work collectively to support and accomplish the proposed research projects, core, educational and training unit and, pilot/trans-network projects, and program evaluation. The Center Advisory Committee (CAC) will bring together investigators with expertise in both the physical sciences and the basic sciences to form a group of voting members. Specifically, the CAC will be made up of the following members: two physical sciences members, Franziska Michor, PhD (PI), and Rong Fan, PhD (core leader); two biological/clinical members, Eric Holland, MD/PhD (PI) and David Scadden, MD (Project 1 leader), a NCI representative, and two external advisors. The staff of the PSOC Administration is committed to provide organizational support and leadership to permit the research projects and core to accomplish their goals and to distribute the accomplishments of each PSOC lab among the PSOC investigators. As such, we have organized appropriate and effective administrative and organizational structures to effectively manage and coordinate all Center research and activities including overall organization, management and communication, trans-network and pilot projects, network activities, and resource sharing.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
3U54CA193461-05S1
Application #
10134497
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Zahir, Nastaran Z
Project Start
Project End
Budget Start
2019-05-01
Budget End
2021-04-30
Support Year
5
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Ozawa, Tatsuya; Arora, Sonali; Szulzewsky, Frank et al. (2018) A De Novo Mouse Model of C11orf95-RELA Fusion-Driven Ependymoma Identifies Driver Functions in Addition to NF-?B. Cell Rep 23:3787-3797
Cimino, Patrick J; Kim, Youngmi; Wu, Hua-Jun et al. (2018) Increased HOXA5 expression provides a selective advantage for gain of whole chromosome 7 in IDH wild-type glioblastoma. Genes Dev 32:512-523
Stein, Shayna; Zhao, Rui; Haeno, Hiroshi et al. (2018) Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients. PLoS Comput Biol 14:e1005924
Hinohara, Kunihiko; Wu, Hua-Jun; Vigneau, Sébastien et al. (2018) KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance. Cancer Cell 34:939-953.e9
Han, Lin; Wu, Hua-Jun; Zhu, Haiying et al. (2017) Bisulfite-independent analysis of CpG island methylation enables genome-scale stratification of single cells. Nucleic Acids Res 45:e77
McDonald, Thomas O; Michor, Franziska (2017) SIApopr: a computational method to simulate evolutionary branching trees for analysis of tumor clonal evolution. Bioinformatics 33:2221-2223
Smith, Kyle S; Liu, Lin L; Ganesan, Shridar et al. (2017) Nuclear topology modulates the mutational landscapes of cancer genomes. Nat Struct Mol Biol 24:1000-1006
Amankulor, Nduka M; Kim, Youngmi; Arora, Sonali et al. (2017) Mutant IDH1 regulates the tumor-associated immune system in gliomas. Genes Dev 31:774-786
Mishima, Yuji; Paiva, Bruno; Shi, Jiantao et al. (2017) The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma. Cell Rep 19:218-224
Yu, H A; Sima, C; Feldman, D et al. (2017) Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers. Ann Oncol 28:278-284

Showing the most recent 10 out of 36 publications